The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The co-administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2-positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interim analysis.
 
Michael Andersson
Honoraria - Celgene; Eisai; Pierre Fabre; Roche Pharma AG
Consulting or Advisory Role - Celgene; Eisai; Pierre Fabre; Roche Pharma AG
Research Funding - Eisai; GlaxoSmithKline; Roche Pharma AG
Travel, Accommodations, Expenses - Celgene; Eisai; Pierre Fabre; Roche Pharma AG
 
José Manuel López-Vega
No Relationships to Disclose
 
Thierry Petit
Consulting or Advisory Role - Novartis; Roche Pharma AG
Travel, Accommodations, Expenses - Novartis; Roche Pharma AG
 
Claudio Zamagni
Consulting or Advisory Role - Fresenius Biotech; Genomic Health; Pierre Fabre; Roche
Travel, Accommodations, Expenses - Celgene; Roche
 
Margarita Donica
Employment - Roche Pharma AG
 
Julia Kamber
Employment - Proacta
Stock and Other Ownership Interests - Proacta
Travel, Accommodations, Expenses - Proacta
 
Edith A. Perez
Research Funding - bioTheranostics (Inst); Genentech (Inst); Genomic Health (Inst); GlaxoSmithKline (Inst); LabCorp (Inst); Nektar (Inst); Novartis (Inst)